Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/30060
Title: Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
Authors: 
Keywords: 
Mesh: 
Issue Date: 2017
Citation: BMC Infect. Dis..2017 10;(17)1:687
Abstract: This study aimed at estimating the efficiency of palivizumab in the prevention of Respiratory Syncytial Virus (RSV) infection and its sequelae in preterm infants (32day 1-35day 0weeks of gestational age -wGA-) in Spain.
PMID: 29041909
URI: https://hdl.handle.net/20.500.12530/30060
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > IIS H. General U. Gregorio Marañón > Artículos

Files in This Item:
File Description SizeFormat 
PMC5645982.pdf1.01 MBAdobe PDFThumbnail
View/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.